As of Feb 16
| 0.00 / 0.00%|
The 2 analysts offering 12-month price forecasts for Cascadian Therapeutics Inc have a median target of 11.50, with a high estimate of 13.00 and a low estimate of 10.00. The median estimate represents a +15.12% increase from the last price of 9.99.
The current consensus among 4 polled investment analysts is to Buy stock in Cascadian Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.